Gene Therapies for Cancer Treatment Market Projects USD 238.77 Billion at 39.94% CAGR by 2034

By GlobeNewswire On Nov 17, 2025

The gene therapies for cancer treatment market size was valued at US$ 11.59 billion in 2025 and is projected to grow to 16.22 billion in 2026. Forecasts suggest it will reach approximately US$ 238.77 billion by 2034, registering a CAGR of 39.94% during the period.

Ottawa, Nov. 17, 2025 (GLOBE NEWSWIRE) — The global gene therapies for cancer treatment market size was valued at USD 8.28 billion in 2024 and is predicted to hit around USD 238.77 billion by 2034, rising at a 39.94% CAGR, a study published by Towards Healthcare a sister firm of Precedence Research. The global gene therapies for cancer treatment market is driven by the expanding healthcare applications and growing innovations.

The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/6314

Key Takeaways

North America held a major revenue share of approximately 42% in the market in 2024.
Asia-Pacific is expected to witness the fastest growth in the gene therapies for cancer treatment market during the forecast period.
By therapy type/modality, the CAR-T cell therapy segment held a major revenue of approximately 35% share of the market in 2024.
By therapy type/modality, the oncolytic virus therapy segment is expected to be the fastest growing in the market over the forecast period.
By cancer type/indication, the hematological cancers segment held a major revenue of approximately 42% share of the market in 2024.
By cancer type/indication, the melanoma & skin cancers segment is expected to witness the fastest growth in the market during the forecast period.
By vector/delivery method, the lentiviral vectors segment held a major revenue of approximately 30% share of the market in 2024.
By vector/delivery method, the non-viral delivery segment is expected to witness the fastest growth in the market during the forecast period.
By treatment setting, the hospital/oncology centers segment held a major revenue of approximately 60% share of the market in 2024.
By treatment setting, the home/outpatient self-administered programs segment is expected to witness the fastest growth in the market during the forecast period.
By distribution channel, the hospital pharmacies/infusion centers segment held a major revenue of approximately 55% share of the market in 2024.
By distribution channel, the direct-to-patient/home delivery segment is expected to witness the fastest growth in the market during the forecast period.

What are the Gene Therapies for Cancer Treatment?

The gene therapies for cancer treatment market is driven by growing cancer prevalence, a strong clinical trials pipeline, and technological advancements. The gene therapies for cancer treatment encompass therapies like CAR T cell therapies, RNA or CRISPR-based therapies, oncolytic viruses, cancer vaccines, suicide gene therapy, and cytokine gene therapies for the treatment of different types of cancers.

You can place an order or ask any questions, please feel free to contact us at [email protected]

Quick Facts Table

Table	Scope
Market Size in 2025	USD 11.59 Billion
Projected Market Size in 2034	USD 238.77 Billion
CAGR (2025 – 2034)	39.94	%
Leading Region	North America by 42%
Market Segmentation	By Therapy Type/Modality, By Cancer Type/Indication, By Vector/Delivery Method, By Treatment Setting, By Distribution Channel, By Region
Top Key Players	Immatics, Legend Biotech, Celyad Oncology, BioNTech, Editas Medicine, Astellas Pharma, Kite Pharma, Allogene Therapeutics, OncoImmune, Takeda, Sangamo Therapeutics, Beam Therapeutics, Charles River Laboratories

What are the Major Growth Drivers in the Market?

Advances in genetic engineering and delivery systems are the major drivers in the gene therapies for cancer treatment market. These advancements are enhancing the safety and effectiveness of the treatment options. Additionally, growing acceptance of CAR-T therapies, R&D investments, combination therapies, growing patient awareness, and demand for personalized medicines are other market drivers.

What are the Key Drifts in the Market?

The gene therapies for cancer treatment market has been expanding due to the growing funding to launch and enhance the use of various cancer gene therapies.

In May 2025, to search for the efficacy of engineered CD4 and CD8 T cells for the treatment of advanced pancreatic cancer, a total of $500,000 grant was provided to the scientists of Fred Hutchinson Cancer Center by Alliance for Cancer Gene Therapy (ACGT) and the Mark Foundation for Cancer Research.
In February 2025, the USC investigators developing a first-of-its-kind genetic therapy for glioblastoma, which is a severe form of brain cancer, were awarded a total of $6 million grant by the California Institute for Regenerative Medicine.

What is the Significant Challenge in the Market?

High treatment costs act as the major challenge in the gene therapies for cancer treatment market. This limits their adoption and acceptance rates by the hospitals as well as the patients. Moreover, complex manufacturing, severe side effects, limited infrastructure, and reimbursement challenges are other market limitations.

Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting

Regional Analysis

Why did North America Dominate the Market in 2024?

In 2024, North America captured the biggest revenue share of 42% in the gene therapies for cancer treatment market, due to the presence of a robust R&D ecosystem. They were further supported by the healthcare investments, where the growing FDA approval enhanced these innovations. Advanced hospitals also increased their use, which contributed to the market growth.

What Made the Asia Pacific Grow Fastest in the Market in 2024?

Asia Pacific is expected to host the fastest-growing gene therapies for cancer treatment market during the forecast period, due to increasing cancer incidences. The expanding healthcare is increasing the demand for these treatment options. Additionally, the growing industries are also increasing their innovations, launches, and manufacturing, promoting the market growth.

Get the latest insights on life science industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership

Segmental Insights

By therapy type/modality analysis

Why Did the CAR-T Cell Therapy Segment Dominate in the Market in 2024?

By therapy type/modality, the CAR-T cell therapy segment led the gene therapies for cancer treatment market with approximately 35% share in 2024, due to its high efficacy. Moreover, they also offered target-specific action, which reduced the side effects. They also provided long-term immune surveillance against cancer.

By therapy type/modality, the oncolytic virus therapy segment is expected to show the highest growth in the market over the upcoming years, due to its dual action, which targets tumor cells and enhances immune responses. This is reducing the side effects and increasing their use in various cancer types. They are also being used in combination with other treatment options.

By cancer type/indication analysis

Which Cancer Type/Indication Type Segment Held the Dominating Share of the Market in 2024?

By cancer type/indication, the hematological cancers segment held the dominating share of approximately 42% of the gene therapies for cancer treatment market in 2024, driven by their specific target identification. They also provided high success rates, which increased their acceptance rates. Moreover, fast approvals increased their R&D.

By cancer type/indication, the melanoma & skin cancers segment is expected to show the fastest growth rate in the market during the upcoming years, due to high immunogenicity. Additionally, the proven success of these therapies is increasing their use with other potential treatment options.

By vector/delivery method analysis

What Made Lentiviral Vectors the Dominant Segment in the Market in 2024?

By vector/delivery method, the lentiviral vectors segment led the gene therapies for cancer treatment market with approximately 30% share in 2024, due to their durable and sustained therapeutic effects. They also provided high transduction efficiency. Furthermore, their large genetic payload capacity also increased their use for cancer treatment.

By vector/delivery method, the non-viral delivery segment is expected to show the highest growth in the market during the upcoming years, driven by its improved safety profile. They also showed minimized immunogenicity, which is increasing their combination with other therapeutic approaches, where their simple manufacturing is also enhancing their use.

By treatment setting analysis

How the Hospital/Oncology Centers Segment Dominated the Market in 2024?

By treatment setting, the hospital/oncology centers segment held the largest share of approximately 60% share of the gene therapies for cancer treatment market in 2024, as they offer complex treatment procedures. They also provided expert supervision, which increased the patient’s trust. Moreover, they also offer post-treatment care, which has also increased the patient outcomes.

By treatment setting, the home/outpatient self-administered programs segment is expected to show the fastest growth rate in the market during the predicted time, as it provides patient convenience and comfort. The growing digital health integrations are also increasing their use, which helps in reducing the number of hospital visits and costs.

By distribution channel analysis

Why Did the Hospital Pharmacies/Infusion Centers Segment Dominate in the Market in 2024?

By distribution channel, the hospital pharmacies/infusion centers segment led the gene therapies for cancer treatment market with approximately 55% share in 2024, as they offer specialized storage and handling of the therapies. They comply with treatment protocol and are directly accessible to the patient, which increased their use.

By distribution channel, the direct-to-patient/home delivery segment is expected to show the highest growth in the market during the predicted time, as this enhances patient convenience. They also provide personalized therapy and remote monitoring, which is enhancing their acceptance rates.

Browse More Insights of Towards Healthcare:

The global gene editing cell line generation service market is on an upward trajectory, poised to generate substantial revenue growth, potentially climbing into the hundreds of millions over the forecast years from 2025 to 2034.

The gene therapy clinical trials market is rapidly advancing on a global scale, with expectations of accumulating hundreds of millions in revenue between 2025 and 2034.

The gene editing therapeutics market is rapidly advancing on a global scale, with expectations of accumulating hundreds of millions in revenue between 2025 and 2034.

The global gene expression market size is calculated at USD 15.45 billion in 2024, grew to USD 16.23 billion in 2025, and is projected to reach around USD 25.26 billion by 2034. The market is expanding at a CAGR of 5.04% between 2024 and 2034.

The global gene vector market size is calculated at US$ 9.61 billion in 2025, grew to US$ 11.64 billion in 2026, and is projected to reach around US$ 64.38 billion by 2035. The market is expanding at a CAGR of 21% between 2026 and 2035.

The global gene knockdown stable cell line service market size recorded US$ 715 million in 2024, set to grow to US$ 774 million in 2025 and projected to hit nearly US$ 1557 million by 2034, with a CAGR of 8.16% throughout the forecast timeline.

The worldwide gene therapy for sickle cell disease market is experiencing significant expansion, with projections indicating a revenue increase reaching several hundred million dollars by the end of the forecast period, spanning 2025 to 2034.

The global gene therapy cell culture media market size began at US$ 193.45 billion in 2024 and is forecast to rise to US$ 214.42 billion by 2025. By the end of 2034, it is expected to surpass US$ 541.42 billion, growing steadily at a CAGR of 10.84%.

The gene synthesis market size is anticipated to grow from USD 2.83 billion in 2025 to USD 10.89 billion by 2034, with a compound annual growth rate (CAGR) of 16.14% during the forecast period from 2025 to 2034.

The gene synthesis service market was estimated at US$ 585 million in 2023 and is projected to grow to US$ 3138.64 million by 2034, rising at a compound annual growth rate (CAGR) of 16.5% from 2024 to 2034.

Recent Developments in the Market

In November 2025, the world’s first humanised CAR-T therapy that is NexCAR19, for the treatment of relapsed or refractory B-cell Non-Hodgkin’s Lymphoma and B-cell Acute Lymphoblastic Leukaemia, was launched in India by ImmunoACT.
In November 2025, a patent is intended to be granted for the use of Reqorsa® Gene Therapy in combination with PD-1 antibodies for cancer treatment by the European Patent Office (EPO) to Genprex, Inc.

Gene Therapies for Cancer Treatment Market Key Players List

Celyad Oncology
Immatics
BioNTech
Legend Biotech
Kite Pharma
Editas Medicine
Astellas Pharma
Oncolmmune
Allogene Therapeutics
Charles River Laboratories
Takeda
Beam Therapeutics
Sangamo Therapeutics

Segments Covered in The Report

By Therapy Type/Modality

CAR-T Cell Therapy
Oncolytic Virus Therapy
TCR (T-cell Receptor) Therapy
Gene Editing/CRISPR-based Therapies
RNA-based Gene Therapies (siRNA/mRNA)
Other/Combination Approaches

By Cancer Type/Indication

Hematological Cancers
Melanoma & Skin Cancers
Solid Tumors
Prostate & Genitourinary Cancers
Other Rare/Pediatric Cancers

By Vector/Delivery Method

Lentiviral Vectors
Non-viral Delivery
Adenoviral/Adeno-Associated Viral (AAV) Vectors
Retroviral Vectors
Other/Hybrid Delivery Approaches

By Treatment Setting

Hospital/Oncology Centers
Home/Outpatient Self-administered Programs
Specialty Cell & Gene Therapy Clinics
Research & Clinical Trial Centers

By Distribution Channel

Hospital Pharmacies/Infusion Centers
Direct-to-Patient/Home Delivery
Specialty Pharmacies/Biotech Distributors
Other (Clinical Trial Supply Channels)

By Region

North America

U.S.
Canada
Mexico
Rest of North America

South America

Brazil
Argentina
Rest of South America

Europe

Western Europe
- Germany
- Italy
- France
- Netherlands
- Spain
- Portugal
- Belgium
- Ireland
- UK
- Iceland
- Switzerland
- Poland
- Rest of Western Europe
Eastern Europe

Austria
Russia & Belarus
Türkiye
Albania
Rest of Eastern Europe

Asia Pacific

China
Taiwan
India
Japan
Australia and New Zealand,
ASEAN Countries (Singapore, Malaysia)
South Korea
Rest of APAC

MEA

GCC Countries
Saudi Arabia
United Arab Emirates (UAE)
Qatar
Kuwait
Oman
Bahrain
South Africa
Egypt
Rest of MEA

Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/checkout/6314

Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

Access the Dashboard: https://www.towardshealthcare.com/access-dashboard

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.

You can place an order or ask any questions, please feel free to contact us at [email protected]

Europe Region: +44 778 256 0738

North America Region: +1 8044 4193 44

APAC Region: +91 9356 9282 04

Web: https://www.towardshealthcare.com

Our Trusted Data Partners

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. NewIndiaObserver.com takes no editorial responsibility for the same.